Reduce Lung Cancer Mortality Research Articles

Lung Cancers Associated with Cystic Airspaces.

Lung cancer, the second most common malignancy in both men and women, poses a significant health burden. Early diagnosis remains pivotal in reducing lung cancer mortality. Given the escalating number of computed tomography (CT) examinations in both outpatient and inpatient settings, radiologists play a crucial role in identifying early-stage pulmonary cancers, particularly non-nodular cancers. Screening programs have been instituted to achieve this goal, and they have raised attention within the scientific community to lung cancers associated with cystic airspaces. These cancers, although they have been known for at least a decade, remain understudied. Limited investigations with small sample sizes have estimated their prevalence and explored their radiological and pathological features. Lung cancers associated with cystic airspaces exhibit varying complexities within their cystic components and demonstrate suspicious changes over time. Adenocarcinoma is the predominant histological type, often with a peripheral location. Differential diagnosis on CT scans includes inflammatory processes or emphysema-related changes. Unfortunately, prospective studies specifically analyzing the prevalence of cystic airspace-associated lung cancers are lacking. However, it is estimated that they constitute approximately one-fourth of delayed radiological diagnoses. Increased awareness among radiologists could lead to more timely identification and potentially reduce lung cancer mortality in a cost-effective manner.

Supporting community translation of lung cancer screening: A web-based decision aid to support informed decision making.

Results of the National Lung Screening Trial create the potential to reduce lung cancer mortality, but community translation of lung cancer screening (LCS) has been challenging. Subsequent policies have endorsed informed and shared decision-making and using decision support tools to support person-centered choices about screening to facilitate implementation. This study evaluated the feasibility and acceptability of LuCaS CHOICES, a web-based decision aid to support delivery of accurate information, facilitate communication skill development, and clarify personal preferences regarding LCS-a key component of high-quality LCS implementation. Using a parallel groups randomized trial, the study investigated the feasibility and acceptability of LuCaS CHOICES decision aid in comparison to the National Cancer Institute's Lung Cancer Screening website. Three waves of self-report data were collected: baseline (PRE), 2 weeks post-baseline (POST), and 4 months post-baseline (FOL). Participant accrual and intervention access data were also collected to evaluate methodological feasibility for conducting a larger subsequent trial. Participants assigned to LuCaS CHOICES (n = 25) and the NCI website (n = 25) interventions reported similar, favorable levels of intervention feasibility and acceptability that exceeded a priori criteria. Methodological feasibility was partially supported for the proposed accrual and retention goals, but accrual was slower than hypothesized, and documented exposure to the digital interventions was suboptimal per a priori standards. Overall, both interventions demonstrated intervention feasibility and acceptability. In addition, the proposed methods achieved desired levels of retention and overall data collection. Modifications to enhance intervention engagement should be explored prior to further testing. Subsequent steps involve conducting a randomized clinical trial to evaluate the effect of LuCaS CHOICES on informed decision making and preference-concordant screening behavior, supporting LCS translation into community settings.

Factors Associated with Smoking Cessation of Participants in the National Lung Cancer Screening Program in Korea.

Smoking cessation interventions for participants in lung cancer screening are essential for increasing the effectiveness of screening to reduce lung cancer mortality. This study aimed to investigate the factors that lead to smoking cessation after lung cancer screening. The Korean National Lung Cancer Screening (KNLCS) Satisfaction Survey was conducted from 2021 to 2022 with 1,000 samples per year among participants in KNLCS targets 30 or more pack-year smokers. Factors associated with smoking cessation were analyzed based on the survey. Among 1,525 current smokers in the survey participants, 728 (47.7%) received screening result counseling from physician after screening and showed significantly higher smoking cessation rate than non-counselling participants [OR 2.17, 95% CI 1.27-3.70]. The participants who considered the counseling helpful were more likely to quit smoking [OR 3.53, 95% CI 2.00-6.22] and to reduce smoking amount [OR 2.05, 95% CI 1.54-2.71]. Similarly, those who received physicians' active recommendations to quit smoking were likely to quit smoking [OR 2.20, 95% CI 1.25-3.87] and to decrease smoking amount [OR 1.30, 95% CI 1.00-1.68]. In contrast, participants who had no abnormal findings from screening tended to have no significant change in smoking status despite the physicians' active recommendations to quit smoking. Physicians' active recommendations and effective counseling to quit smoking could be a key factor in increasing smoking cessation among lung cancer screening participants. Further research should be conducted to develop more effective strategies for smoking cessation to participants without abnormal findings in lung cancer screening.

Peripheral Extracellular Vesicles for Diagnosis and Prognosis of Resectable Lung Cancer: The LUCEx Study Protocol.

Background/Objectives: Lung cancer is the primary cause of cancer-related deaths. Most patients are typically diagnosed at advanced stages. Low-dose computed tomography (LDCT) has been proven to reduce lung cancer mortality, but screening programs using LDCT are associated with a high number of false positives and unnecessary thoracotomies. It is therefore imperative that a certain diagnosis is refined, especially in cases of solitary pulmonary nodules that are difficult to technically access for an accurate preoperative diagnosis. Extracellular vesicles (EVs) involved in intercellular communication may be an innovative biomarker for diagnosis and therapeutic strategies in lung cancer, regarding their ability to carry tumor-specific cargo. The aim of the LUCEx study is to determine if extracellular vesicle cargoes from both lung tissue and blood could provide complementary information to screen lung cancer patients and enable personalized follow-up after the surgery. Methods: The LUCEx study is a prospective study aiming to recruit 600 patients with lung cancer and 50 control subjects (false positives) undergoing surgery after diagnostic imaging for suspected pulmonary nodules using computed tomography (CT) scans. These patients will undergo curative surgery at the Department of Thoracic Surgery of the Miguel Servet Hospital in Zaragoza, Spain, and will be followed-up for at least 5 years. At baseline, samples from both tumor distal lung tissue and preoperative peripheral blood will be collected and processed to compare the quantity and content of EVs, particularly their micro-RNA (miRNA) cargo. At the third and fifth years of follow-up, CT scans, functional respiratory tests, and blood extractions will be performed. Discussion: Extracellular vesicles and their miRNA have emerged as promising tools for the diagnosis and prognosis of several diseases, including cancer. The LUCEx study, based on an observational clinical cohort, aims to understand the role of these vesicles and their translational potential as complementary tools for imaging diagnosis and prognosis.

Lung Cancer Screening Uptake under the Revised United States Preventive Services Task Force Guideline: Assessing Disparities.

Scanning with low-dose computed tomography reduces lung cancer mortality by 20% among high-risk individuals. Despite its efficacy, the uptake of lung cancer screening (LCS) remains low. Our study aimed to estimate state-level and nationwide LCS rates among eligible individuals and to assess disparities in LCS uptake. Data for this study were obtained from the 2022 Behavioral Risk Factor Surveillance System. Multivariable logistic regression models were used to model the associations between predictors and outcome variables and to examine LCS variability across states. Of the 28,071 participants eligible for LCS, 17.24% underwent LCS. Participants ages 65 to 79 years were [OR, 1.75; 95% confidence interval (CI), 1.54-1.99] more likely to undergo LCS than their younger counterparts. Those who were female (OR, 0.83; 95% CI, 0.73-0.94); divorced, separated, or widowed (OR, 0.85; 95% CI, 0.74-0.98); without health insurance (OR, 0.34; 95% CI, 0.22-0.53); without a primary care provider (OR, 0.29; 95% CI, 0.19-0.44); and without chronic obstructive pulmonary disease or those who did not disclose their chronic obstructive pulmonary disease status (OR, 0.35; 95% CI, 0.31-0.40 and OR, 0.37; 95% CI, 0.19-0.73, respectively) were less likely to undergo LCS than their respective counterparts. LCS uptake also varied significantly across U.S. states. We observed a low uptake of LCS overall and significant variability in LCS uptake by sociodemographic and health-related factors, as well as by state of residence. The findings from this study have important implications for community health workers and healthcare clinicians and indicate the need to design effective interventions to increase LCS uptake, targeting specific subgroups of populations and particular U.S. states. See related In the Spotlight, p. 9.

Protocol for a systematic review and individual participant data meta-analysis for risk factors for lung cancer in individuals with lung nodules identified by low-dose CT screening

BackgroundWorldwide, lung cancer (LC) is the second most frequent cancer and the leading cause of cancer related mortality. Low-dose CT (LDCT) screening reduced LC mortality by 20–24% in randomised trials...

Lung cancer screening program quality indicators - review & recommendations - An International Association for the Study of Lung Cancer Delphi process study.

Lung cancer screening (LCS) using low-dose-computed tomography reduces lung cancer mortality in high-risk individuals. Evaluating and monitoring LCS programs are important to ensure and improve quality, efficiency and participant outcomes. There is no agreement on LCS quality indicators (QIs). Twenty multidisciplinary members of IASLC used a Delphi process to develop consensus Qis. They considered 50 Qis during information/discussion sessions and two anonymous voting rounds. ≥80% voting agree/strongly agree on a five-point Likert scale determined consensus. Twenty essential and six desirable QIs were identified in 10 of 11 LCS pathway domain categories: ENTRY: Proportion eligible who got screened. SMOKING_CESSATION: Proportion current-smoking individuals offered cessation interventions. Proportion screened requiring clinical diagnostic assessment, scans results distribution, proportion scans requiring early follow-up, proportion baseline/regular scans with actionable additional findings. Annual/regular scans, early interim scans, clinical diagnostic assessment. Proportion suspicious-for-lung-cancer scans receiving clinical investigation, undergoing invasive diagnostic procedures. Cancer detection rate, stage distribution, interval cancer rate HARMS: Number/proportion of serious complications following invasive procedures, non-lung cancer diagnoses following invasive procedures, or following surgery, 30-day mortality following invasive procedure. Proportion early-stage cancers receiving treatment with curative intent. WAIT_TIMES: Suspicious-for-lung-cancer scan to definitive diagnosis, curative-intent treatment for individuals with early-stage disease, scan completion to reporting results to PCP/participant. Race/sex/socioeconomic differences in adherence to regular screens, early-stage cancer treatment, offer of smoking cessation interventions, clinical investigation of suspicious-for-lung-cancer screens. Review among panel members provide recommended LCS QIs that should be considered in development of LCS initiatives .

Prospective Evaluation of Lung Cancer Screening Eligibility Criteria and Lung Cancer Detection in the Yorkshire Lung Screening Trial.

Low-dose computed tomography screening for lung cancer reduces lung cancer mortality, but there is a lack of international consensus regarding the optimal eligibility criteria for screening. The Yorkshire Lung Screening Trial was designed to evaluate lung cancer screening (LCS) implementation, and a primary objective was prospective evaluation of three predefined eligibility criteria. Individuals who had ever smoked, aged 55 to 80 years, who responded to written invitation, underwent telephone risk assessment and if eligible by at least one criterion (PLCOM2012 ≥ 1.51%, LLPv2 ≥ 5%, USPSTF2013) were offered biennial low-dose computed tomography screening. Of 44,957 individuals invited, 22,814 responded and underwent eligibility assessment, of whom a total of 7826 were eligible according to any of the three LCS criteria. Comparing PLCOM2012 ≥ 1.51%, LLPv2 ≥ 5%, and USPSTF2013, the proportions of responders eligible for screening were 28.0%, 20.5%, and 18.9%, respectively (p < 0.0001 for each comparison), and the proportion of all cancers detected 91.1%, 77.0%, and 62.8%, respectively (p ≤ 0.0002 for each comparison). When risk thresholds were selected to result in equivalent numbers of people eligible for screening, cancer detection proportions were higher for PLCOM2012 (74.5%) and LLPv2 (71.3%) than USPSTF2013 (62.8%) (p= 0.0002 and p= 0.032, respectively), but there was no significant difference between the two risk models. Reducing the LLPv2 risk threshold from 5% to 2.5% (as currently used in the English LCS program) and reducing the pack-year requirement for the USPSTF2021 versus the USPSTF2013 criteria increased the numbers eligible for screening, but subsequent cancer yield was not measured in this study. The PLCOM2012 ≥ 1.51% criteria identified more people eligible for screening in Yorkshire Lung Screening Trial and resulted in more screen-detected lung cancers than LLPv2 ≥ 5% or USPSTF2013. When compared in equivalent populations, there was no significant difference between risk models in terms of lung cancer detection and each appeared more efficient at screening population selection than USPSTF2013.

Missed Opportunities for Lung Cancer Screening Among Patients With Behavioral Health Disorders With Elevated Cigarette Smoking Rates: Lung Cancer Screening and Behavioral Health.

Annual lung cancer screening using low-dose CT (LDCT) imaging effectively reduces mortality from lung cancer and is recommended for people who are at high risk of developing the disease. The utilization of lung cancer screening, however, has remained low. Due to significantly higher cigarette smoking rates, patients with behavioral health disorders (those living with mental illness and/or substance use disorders) are more likely to be diagnosed with and die of lung cancer; at the same time, they are less likely to undergo cancer screenings. There is an urgent need for targeted efforts to improve access to lung cancer screening among this population disproportionately affected by the disease. In this commentary, we propose integrating lung cancer screening facilitation into services provided by behavioral health professionals who are uniquely positioned to reach these patients and deliver interventions to increase uptake of cancer screenings. We suggest several measures that could improve lung health outcomes of patients with behavioral health disorders: (1) training behavioral health professionals in lung cancer screening eligibility assessment; (2) providing patients with educational materials; (3) integrating shared decision-making counseling for lung cancer screening into behavioral health care settings; (4) providing the practical support needed to access screening; and (5) establishing effective partnerships with community organizations. Regardless of the level of engagement, possibly ranging from brief training to the implementation of comprehensive programs, any involvement will benefit patients. This integrated approach will contribute to reducing lung cancer mortality among patients with behavioral health disorders who have long experienced systemic health inequities.

Lung Cancer Screening With Low-Dose CT: A Systematic Review.

Lung cancer is highly prevalent worldwide and is the leading cause of cancer-related death in Portugal. There is increasing evidence that low-dose computed tomography (LDCT) screening reduces mortality; however, few countries have implemented screening strategies. This review aims to gather the best evidence to assess the relevance of implementing lung cancer screening. A search was conducted for clinical practice guidelines (CPGs), systematic reviews (SRs), and meta-analyses (MAs) published between January 1, 2010, and January 31, 2024, as well as randomized controlled trials (RCTs) published between January 1, 2019, and January 31, 2024, indexed in databases such as the National Guideline Clearinghouse, Cochrane Library, Guideline Finder, Canadian Medical Association, Evidence-Based Medicine Online, Database of Abstracts of Reviews of Effectiveness (DARE), and PubMed. The MeSH terms used were "lung cancer" and "screening". To evaluate the level of evidence (LE) and strength of recommendation (SR) in the included MAs, the Strength of Recommendation Taxonomy (SORT) from the American Academy of Family Physicians was applied. A total of 460 articles were found, with two CPGs, six MAs, two SRs, and one RCT being selected. The CPGs recommend screening with LDCT for smokers with a smoking history of more than 20 pack-years, aged between 50 and 80 years. All MAs show statistically significant evidence of reduced mortality in screened patients, although without a reduction in all-cause mortality. However, there was some heterogeneity regarding the age of the target population and the screening follow-up period. Overdiagnosis rates varied between MAs. The SRs and RCT also demonstrated a reduction in lung cancer mortality, but not in all-cause mortality. LDCT lung cancer screening shows a reduction in disease-related mortality, suggesting that the implementation of organized screening for at-risk populations could have a significant positive impact. Some uncertainties remain regarding the best strategy for implementing organized screening programs.

A calibrated model for lung cancer natural history: the case for New Zealand

ABSTRACT A microsimulation model is an ideal tool to evaluate the impact of the new health screening programme. Health policymakers in New Zealand are reviewing international evidence on lung cancer screening with the aim of reducing lung cancer mortality through early detection. In this study, we developed and calibrated a New Zealand specific microsimulation model for the natural history of lung cancer. This is the first time a lung cancer microsimulation model has been developed for New Zealand. We adapted simulation steps devised for the MIcrosimulation Lung Cancer (MILC) model (Chrysanthopoulou, 2017). The simulation steps include a Gompertz tumour growth component, disease progression based on log-normal distributions and a survival component. Simulated lung cancer rates at different disease stages (i.e. local, regional, and distant) and at diagnosis were used to calibrate and validate model parameters to data from the New Zealand (NZ) lung cancer registry. We used the Bayesian approach to calibrate the model parameters using the Hamiltonian Monte Carlo (HMC) approach, which is not commonly employed in the field of cancer modelling. The calibrated model was able to predict general trends in lung cancer incidence by age group when compared to lung cancer incidence in NZ.

CD47 expression in non-small cell lung cancer and its relationship with tumor-associated macrophage infiltration.

Non-small cell lung cancer (NSCLC) has a high incidence, with most patients diagnosed beyond the optimal surgical window. Improving survival rates is critical to reducing lung cancer mortality, and identifying immune checkpoints is vital for prognosis stratification. To investigate the expression of CD47 in NSCLC and its relationship with tumor-associated macrophage infiltration. A retrospective analysis was conducted on 50 NSCLC patients treated between January 2014 and June 2018. Immunohistochemistry and confocal microscopy assessed CD47 expression in tumor and adjacent tissues, while immunofluorescence evaluated CD47 on tumor-infiltrating T lymphocytes. Kaplan-Meier survival analysis and Cox regression identified prognostic factors, and PLA technology examined CD47's interaction with VEGFR and CD36. CD47 positivity in tumor tissues (52%) was significantly higher than in adjacent tissues (20%) (P<0.001), with expression localized to the cell membrane. CD47 expression correlated with lymph node metastasis, clinical stage, and differentiation (P<0.05) and was identified as an independent risk factor for poor prognosis. TAM infiltration was greater in CD47-positive patients and correlated with shorter survival (P<0.05). PLA showed stronger CD47+VEGFR interactions than CD47+CD36. CD47 positivity correlates with poor prognosis and increased TAM infiltration, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC.

The electronic nose in lung cancer diagnostics: A systematic review and meta-analysis

BackgroundLung cancer remains a leading cause of cancer-related deaths. Early-stage detection is pivotal for curative interventions, yet most cases are diagnosed at advanced stages. Non-invasive point-of-care diagnostic strategies are needed to reduce lung cancer mortality rates. We assess the potential of electronic nose (eNose) devices as a tool for lung cancer detection.Study design and methodsAll online available databases were searched. Following PRISMA guidelines, we reviewed studies utilising eNose forin vivoexhaled air analysis in lung cancer patients. Included patients had pathological confirmed lung cancer, both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in various stages. Primary outcomes were sensitivity, specificity, negative predictive value and area under the curve. Secondary outcomes evaluated eNose performance in distinguishing NSCLC subtypes and SCLC. Additionally, a subgroup analysis was conducted to evaluate the efficacy of various commonly used sensors in this differentiation. The QUADAS-2 tool was used for risk-of-bias assessment.ResultsThirty-five studies, comprising 4483 patients, were included. Pooled sensitivity and specificity were 0.90 (CI 0.87–0.93) and 0.89 (0.85–0.93), respectively. Median negative predictive value was 0.93 and median area under the curve was 0.91. Both the likelihood of bias and concerns regarding applicability were minimal.InterpretationeNose devices hold promise as non-invasive, point-of-care tools for lung cancer diagnosis. Due to high sensitivity and negative predictive value, and great ease of use they might be valuable additions to the diagnostic toolbox. Further research and validation efforts are critical to maximise their impact on early lung cancer detection.

Changes in Staging and Management of Non-Small Cell Lung Cancer (NSCLC) Patients Following the Implementation of Low-Dose Chest Computed Tomography (LDCT) Screening at Kaohsiung Medical University Hospital.

Low-dose computed tomography (LDCT) has been widely adopted for lung cancer screening due to its proven ability to reduce lung cancer mortality, especially among high-risk populations. This retrospective study aims to evaluate the impact of LDCT screening on non-small cell lung cancer (NSCLC) staging at Kaohsiung Medical University Hospital (KMUH) from 2011 to 2020, following the introduction of LDCT in 2013. The study examines the correlation between LDCT screening volume and changes in the distribution of NSCLC stages, particularly early-stage (stages 0 and I) and late-stage (stage IV) diagnoses. Additionally, it explores the differences in histopathological subtypes, focusing on adenocarcinoma and squamous cell carcinoma, and assesses the impact of early detection on five-year survival rates. The results show a significant increase in early-stage NSCLC diagnoses, particularly in adenocarcinoma cases, where early-stage diagnoses rose from 10.4% in 2010 to 38.7% in 2019. However, the number of stage IV cases remained stable, indicating that LDCT may not substantially reduce late-stage diagnoses. Pearson's correlation analysis demonstrated a strong positive correlation between LDCT screening and early-stage NSCLC detection, particularly for adenocarcinoma (p < 0.001), though the early detection of squamous cell carcinoma and small cell carcinoma remained limited. The study concludes that LDCT screening plays a crucial role in improving early NSCLC detection and five-year survival rates. Future research should focus on optimizing screening strategies to capture more at-risk populations and enhance the detection of harder-to-diagnose subtypes like squamous cell carcinoma.

Cost-effectiveness of lung cancer screening with volume computed tomography in Portugal.

Aim: Lung cancer is the most common cause of cancer death in Portugal. The Dutch-Belgian lung cancer screening (LCS) study (NELSON), the biggest European LCS study, showed a lung cancer mortality reduction in a high-risk population when being screened. In this study, the cost-effectiveness of LCS, based on the NELSON study protocol and outcomes, was evaluated compared with no screening in Portugal. Methods: The present study modified an established decision tree by incorporating a state-transition Markov model to evaluate the health-related advantages and economic implications of low-dose computed tomography (LDCT) LCS from the healthcare standpoint in Portugal. The analysis compared screening versus no screening for a high-risk population aged 50-75 with a smoking history. Various metrics, including clinical outcomes, costs, quality-adjusted life years (QALYs), life-years (LYs) and the incremental cost-effectiveness ratio (ICER), were calculated to measure the impact of LDCT LCS. Furthermore, scenario and sensitivity analyses were executed to assess the robustness of the obtained results. Results: Annual LCS with volume-based LDCT resulted in €558million additional costs and 86,678 additional QALYs resulting in an ICER of €6440 per QALY for one screening group and a lifetime horizon. In total, 13,217 premature lung cancer deaths could be averted, leading to 1.41 additional QALYs gained per individual diagnosed with lung cancer. Results are robust based on the sensitivity analyses. Conclusion: This study showed that annual LDCT LCS for a high-risk population could be cost-effective in Portugal based on a willingness to pay a threshold of one-time the GDP (€19,290 per QALY gained).

Lung nodule classification using radiomics model trained on degraded SDCT images

Background and objectiveLow-dose computed tomography (LDCT) screening has shown promise in reducing lung cancer mortality; however, it suffers from high false positive rates and a scarcity of available annotated datasets. To overcome these challenges, we propose a novel approach using synthetic LDCT images generated from standard-dose CT (SDCT) scans from the LIDC-IDRI dataset. Our objective is to develop and validate an interpretable radiomics-based model for distinguishing likely benign from likely malignant pulmonary nodules. MethodsFrom a total of 1010 CT images (695 SDCTs and 315 LDCTs), we degraded SDCTs in the sinogram domain and obtained 1950 nodules as the training set. The 675 nodules from the LDCTs were stratified into 50%-50% partitions for validation and testing. Radiomic features were extracted from nodules, and three feature sets were assessed using: a) only shape and size (SS) features, b) all features but SS features, and c) all features. A systematic pipeline was developed to optimize the feature set and evaluate multiple machine learning models. Models were trained using degraded SDCT, validated and tested on the LDCT nodules. ResultsTraining a logistic regression model using three SS features yielded the most promising results, achieving on the test set mean balanced accuracy, sensitivity, specificity, and AUC-ROC scores of 0.81, 0.76, 0.85, and 0.87, respectively. ConclusionsOur study demonstrates the feasibility and effectiveness of using synthetic LDCT images for developing a relatively accurate radiomics-based model in lung nodule classification. This approach addresses challenges associated with LDCT screening, offering potential implications for improving lung cancer detection and reducing false positives.

The TELEhealth Shared decision-making COaching and navigation in Primary carE (TELESCOPE) intervention: a study protocol for delivering shared decision-making for lung cancer screening by patient navigators.

Lung cancer screening (LCS) can reduce lung cancer mortality but has potential harms for patients. A shared decision-making (SDM) conversation about LCS is required by the Centers for Medicare & Medicaid Services (CMS) for LCS reimbursement. To overcome barriers to SDM in primary care, this protocol describes a telehealth decision coaching and navigationintervention for LCS in primary care clinics delivered by patient navigators. The objective of the study is to evaluate the effectiveness of the intervention and its implementation potential, compared with an enhanced usual care (EUC) arm. Patients (n = 420) of primary care clinicians (n = 120) are being recruited to a cluster randomized controlled trial. Clinicians are randomly assigned to 1) TELESCOPE intervention: prior to an upcoming non-acute clinic visit, patients participate in a telehealth decision coaching and navigationsession about LCS delivered by trained patient navigators and nurse navigators place a low-dose CT scan (LDCT) order for each TELESCOPE patient wanting LCS, or 2) EUC: patients receive enhanced usual care from a clinician. Usual care is enhanced by providing clinicians in both arms with access to a Continuing Medical Education (CME) webinar about LCS and an LCS discussion guide. Patients complete surveys at baseline and 1-week after the scheduled clinic visit to assess quality of the SDM process. Re-navigation is attempted with TELESCOPE patients who have not completed the LDCT within 3months. One month before being due for an annual screening, TELESCOPE patients whose initial LCS showed low-risk findings are randomly assigned to receive a telehealth decision coaching booster session with a navigator or no booster. Electronic health records are abstracted at 6, 12 and 18months after the initial decision coaching session (TELESCOPE) or clinic visit (EUC) to assess initial and annual LCS uptake, imaging results, follow-up testing for abnormal findings, cancer diagnoses, treatment, and tobacco treatment referrals. This study will evaluate factors that facilitate or interfere with program implementation using mixed methods. We will assess whether a decision coaching and patient navigation intervention can feasibly and effectivelysupport high-quality SDM for LCS and guideline-concordant LCS uptake for patients in busy primary care practices serving diverse patient populations. This study was registered at ClinicalTrials.gov (NCT05491213) on August 4, 2022. Version 1, April 10, 2024.

Public perspectives on the benefits and harms of lung cancer screening: A systematic review and mixed-method integrative synthesis.

Screening for lung cancer with low dose computed tomography aims to reduce lung cancer mortality, but there is a lack of knowledge about how target populations consider its potential benefits and harms. We conducted a systematic review of primary empirical studies published in any jurisdiction since 2002 using an integrative meta-synthesis technique. We searched six health and social science databases. Two reviewers independently screened titles, abstracts, and potentially eligible full-text studies. Quantitative assessments and open-ended perspectives on benefits and harms were extracted and convergently integrated at analysis using a narrative approach. Study quality was assessed. The review included 26 quantitative, 18 qualitative, and 5 mixed methods studies. Study quality was acceptable. Lung cancer screening was widely perceived to be personally beneficial for early detection and reassurance. Radiation exposure and screening accuracy were recognised as harms, but these were frequently considered to be justified by early detection of lung cancer. Stigma, anxiety, and fear related to screening procedures and results were pervasive among current smokers. People with low incomes reported not participating in screening because of potential out-of-pocket costs and geographic access. Populations targeted for lung cancer screening tended to consider screening as personally beneficial and rationalised physical, but not psychological, harms. Screening programmes should be clear about benefits, use non-stigmatising design, and consider equity as a guiding principle.

Disparities in lungcancerscreening utilization attwo health systems in the Southeastern USA.

Low-dose computed tomography lung cancer screening is effective for reducing lung cancer mortality. It is critical to understand the lung cancer screening practices for screen-eligible individuals living in Alabama and Georgia where lung cancer is the leading cause of cancer death. High lung cancer incidence and mortality rates are attributed to high smoking rates among underserved, low income, and rural populations. Therefore, the purpose of this study is to define sociodemographic and clinical characteristicsof patients who were screened for lung cancer at an Academic Medical Center (AMC) in Alabama and a Safety Net Hospital (SNH) in Georgia. A retrospective cohort study of screen-eligible patients was constructed using electronic health records between 2015 and 2020 seen at an Academic Medical Center (AMC) and a Safety Net Hospital (SNH) separately. Chi-square tests and Student t tests were used to compare screening uptake across patient demographic and clinical variables. Bivariate and multivariate logistic regressions determined significant predictors of lung cancer screening uptake. At the AMC, 67,355 were identified as eligible for LCS and 1,129 were screened. In bivariate analyses, there were several differences between those who were screened and those who were not screened. Screening status in the site at Alabama-those with active tobacco use are significantly more likely to be screened than former smokers (OR: 3.208, p < 0.01). For every 10-unit increase in distance, the odds of screening decreased by about 15% (OR: 0.848, p < 0.01). For every 10-year increase in age, the odds of screening decrease by about 30% (OR: 0.704, p < 0.01). Each additional comorbidity increases the odds of screening by about 7.5% (OR: 1.075, p < 0.01). Those with both private and public insurance have much higher odds of screening compared to those with only private insurance (OR: 5.403, p < 0.01). However, those with only public insurance have lower odds of screening compared to those with private insurance (OR: 0.393, p < 0.01). At the SNH-each additional comorbidity increased the odds of screening by about 11.9% (OR: 1.119, p = 0.01). Notably, those with public insurance have significantly higher odds of being screened compared to those with private insurance (OR: 2.566, p < 0.01). The study provides evidence that LCS has not reached all subgroups and that additional targeted efforts are needed to increase lung cancer screening uptake. Furthermore, disparity was noticed between adults living closer to screening institutions and those who lived farther.

Lung cancer screening by low-dose CT scan in France: final results of the DEP KP80 study after three rounds

In prior randomised controlled trials, lung cancer screening using low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality and overall mortality. Despite these results, organised screening in France remains a challenge. This study assessed the feasibility and efficacy of lung cancer screening within a real-life context in a French administrative territory. DEP KP80 was a single-arm prospective study. Participants aged between 55 and 74 years, smokers or former smokers of ≥30 pack-years, were recruited. An annual LDCT scan was scheduled and three rounds were performed. Subjects were selected by general practitioners or pulmonologists, who checked the inclusion criteria and prescribed the CT scan. Between March 2016 and February 2020, 1254 participants were enrolled. Overall, 945 (75.4%) participants underwent baseline LDCT (T0), 376 (42.8%) completed the first round (T1) and 270 (31%) the second (T2) one. Forty-two lung cancers were diagnosed, 30 cancers (71.4%) were stage I or II and 34 cancers (80.9%) were treated surgically. In this study, the overall positive predictive value for a positive screening was 48% (95% CI 37-59) and the negative predictive value 100% (95% CI 100-100). This study demonstrated the feasibility and efficacy of lung cancer screening in a real-life context with most lung cancers diagnosed at an early stage and surgically removed. Our results also highlighted the importance of participation in each round, underlining the fact that optimising organisation is a major goal. Agence Régionale de Santé de Picardie, La Ligue contre le cancer, le Conseil Départemental de la Somme, and AstraZeneca.